Individuals with type 2 diabetes who have not achieved adequate blood sugar control with other oral medications or who require additional treatment beyond oral medications may be candidates for GLP-1 therapy
Thats approximately 11 million people whose disease management likely involves direct medical expenses associated with hospitalizations, medications, regular monitoring and worsening comorbidities, as well as indirect costs like lost productivity and long-term disability care
GHK-Cu works best as part of a consistent routine that also includes gentle cleansing, moisturizer and daily sunscreen
These changes reflect your GLP-1 receptors no longer receiving the medication's signal to suppress appetite and slow digestion
Your provider needs to document that you meet specific criteria, typically a BMI of 30 or higher, or 27 or higher with at least one weight-related comorbidity (hypertension, dyslipidemia, type 2 diabetes, obstructive sleep apnea, etc.)
Generally yes, with monitoring
